(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies...
Stats | |
---|---|
本日の出来高 | 26 918.00 |
平均出来高 | 60 636.00 |
時価総額 | 241.06M |
EPS | £0 ( 2024-04-30 ) |
Last Dividend | £14.20 ( 2023-07-27 ) |
Next Dividend | £0 ( N/A ) |
P/E | 37.61 |
ATR14 | £3.22 (0.50%) |
ボリューム 相関
International 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
International 相関 - 通貨/商品
International 財務諸表
Annual | 2023 |
収益: | £8.49M |
総利益: | £8.49M (100.00 %) |
EPS: | £0.170 |
FY | 2023 |
収益: | £8.49M |
総利益: | £8.49M (100.00 %) |
EPS: | £0.170 |
FY | 2022 |
収益: | £-21.10M |
総利益: | £-21.10M (100.00 %) |
EPS: | £-0.550 |
FY | 2021 |
収益: | £29.12M |
総利益: | £0.00 (0.00 %) |
EPS: | £0.725 |
Financial Reports:
No articles found.
International Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£15.70 (N/A) |
£14.00 (N/A) |
£0 (N/A) |
£0 (N/A) |
£14.20 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £1.000 | 1995-11-13 |
Last Dividend | £14.20 | 2023-07-27 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | £191.80 | -- |
Avg. Dividend % Per Year | 2.11% | -- |
Score | 4.55 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.50 | |
Div. Directional Score | 8.52 | -- |
Year | Amount | Yield |
---|---|---|
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £41.00 | 7.36% |
2019 | £26.40 | 4.63% |
2020 | £26.60 | 4.28% |
2021 | £29.90 | 3.70% |
2022 | £29.70 | 4.04% |
2023 | £14.20 | 1.97% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TND.L | Dividend Junior | 2023-05-11 | Semi-Annually | 31 | 1.44% | |
LUCE.L | Dividend Knight | 2023-09-14 | Annually | 8 | 2.16% | |
COST.L | Dividend Knight | 2023-09-21 | Annually | 17 | 0.27% | |
RST.L | Dividend Junior | 2023-09-21 | Annually | 13 | 0.98% | |
HIK.L | Dividend Knight | 2023-08-10 | Semi-Annually | 19 | 1.60% | |
AZN.L | Ex Dividend Knight | 2023-08-10 | Semi-Annually | 32 | 1.07% | |
VIC.L | Dividend Knight | 2023-06-08 | Semi-Annually | 2 | 0.88% | |
MRO.L | Dividend Junior | 2023-09-14 | Semi-Annually | 19 | 2.42% | |
DNA3.L | Dividend Royal | 2023-07-20 | Quarterly | 12 | 10.69% | |
SHOE.L | Dividend Knight | 2023-07-13 | Annually | 10 | 2.57% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.651 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0223 | 1.200 | 9.26 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0241 | 1.500 | -0.844 | -1.265 | [0.1 - 1] |
payoutRatioTTM | 1.674 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 19.01 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 19.01 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0.213 | -1.500 | 6.45 | -9.67 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.676 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.676 | 2.00 | 9.66 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.240 | -1.500 | 9.04 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.629 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.420 | 1.000 | 8.78 | 8.78 | [0.2 - 2] |
assetTurnoverTTM | 0.0343 | 0.800 | -3.10 | -2.48 | [0.5 - 2] |
Total Score | 10.54 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 37.45 | 1.000 | 6.32 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0241 | 2.50 | -0.542 | -1.265 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.676 | 2.00 | 9.77 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.45 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.676 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.674 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 28.61 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 2.61 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 6.50 |
International
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of these companies to strategic buyers including major pharmaceutical companies or, in some cases, and through a flotation.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。